COST-EFFECTIVENESS ANALYSIS OF INSULIN REGIMEN ON TYPE 2 DIABETES MELLITUS OUTPATIENT IN DENPASAR MUNICIPALITY
Objective: Insulin is one of the antidiabetic agents that available for the treatment of type 2 diabetes mellitus (T2DM) patients. Insulin has several types of formulation, with its cost and effectiveness. The aim of this study was to compare the cost-effectiveness of insulin regimen in the therapy management of T2DM outpatient.
Methods: Cost-effectiveness analysis has been done by calculating the average cost-effectiveness ratio (ACER) and incremental cost-effectiveness ratio (ICER) of each insulin regimens. Effectiveness was measured by improvement of fasting blood glucose, postprandial blood glucose, and HbA1c value. The total cost of insulin regimen was calculated from direct medical cost, direct nonmedical cost, and indirect nonmedical cost.
Results: Overall, 42 patients meet the inclusion criteria were included this study. There were four insulin regimens compared, namely, insulin detemir,premixed insulin aspart, insulin aspart, and a combination of insulin aspart + insulin glargine. The combination of insulin aspart + insulin glargine provides pre-eminent therapy effectiveness (58.82%), whereas insulin detemir regimen has the lowest total cost (102.62 USD). Calculation of ACER showed that insulin aspart has the lowest ACER value, in an amount of 1.91 USD per percentage of effectiveness. Based on ICER value, insulin aspart was the better choice compared to the combination of insulin aspart + insulin glargine (0.18 USD vs. 0.82 USD).
Conclusion: The variation of therapeutic effectiveness and total cost was observed in the management of T2DM outpatient. Based on ACER and ICER value, insulin aspart was the most cost-effective insulin compared to another insulin regimen on the study.
2. American Diabetes Association. Economic costs of diabetes in the U.S.in 2012. Diabetes Care 2013;36:1033-46.
3. Hussain M, Naqvi SB, Khan MA, Rizvi M, Alam S, Abbas A, et al.Direct cost of treatment of diabetes mellitus Type 2 in Pakistan. Int J Pharm Pharm Sci 2014;6:261-4.
4. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for Type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S253-9.
5. Petznick A. Insulin management of Type 2 diabetes mellitus. Am Fam Physician 2011;84:183-90.
6. Triplitt AK, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, WellsBG, Posey LM, editors. Pharmacotherapy: A Patophysiologic Approach. 7th ed. New York: McGraw Hill; 2008.
7. Caporale JE, PichÃ³n-Riviere A, Beratarrechea AG, Von Schulz-Hausmann C, Augustovski F. A Comparison of 1-year treatment costs in patients with Type 2 diabetes following initiation of insulin glargine or insulin detemir in Argentina. Value Health Reg Issues 2014;5C:14-9.
8. Helble M, Aizawa T. International Trade and Determinants of Price Differentials of Insulin Medicine. ADBI Working Paper 551. Tokyo:
Asian Development Bank Institute; 2015. Available from: http://www.adb.org/publications/international-trade-and-determinantspricedifferentials-insulin-medicine. [Last accessed on 2017 Jan 20].
9. Svensson AM, Lak V, Fard MP, Eliasson B. Total costs of basal or premixed insulin treatment in 5077 insulin-naÃ¯ve Type 2 diabetes patients: Register-based observational study in clinical practice. Clin Diabetes Endocrinol 2015;1:17.
10. Phillips C. What is Cost Effectiveness?: Health Economic. 2nd ed.Canada: Swansea University; 2009.
11. Skrepnek GH. Cost Effectiveness Analysis. USA: Harvey Whitney Books Company; 2005.
12. Edejer TT, Baltussen L, Adam T, Hutubessy R, Acharya A, Evans DB,et al. WHO guide to cost-effectiveness analysis. Switzerland: World Health Organization; 2003.
13. Rudijanto A, Yuwono A, Shahab A, Manaf A, Pramono B, Lindarto D,et al. Consensus of management and prevention of diabetes mellitus Type 2 in Indonesia 2015. Jakarta, Indonesia: PB Perkeni; 2015.
14. Cefalu WT, Bakris G, Blonde L, Boulton AJ, Dâ€™Alessio D, Golden SH,et al. Standards of medical care in diabetes-2016. Diabetes Care 2016;39 Suppl 1:S52-9.
15. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S,et al. Addition of biphasic, prandial, or basal insulin to oral therapy in Type 2 diabetes. N Engl J Med 2007;357:1716-30.
16. Holt RI. Insulin initiation in Type 2 diabetes: The implications of the 4-T study. Diabet Med 2010;27:1-3.
17. Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G,et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with Type 2 diabetes. Diabetes Obes Metab 2012;14:901-9.
18. Bang H, Zhao H. Average cost-effectiveness ratio with censored data.J Biopharm Stat 2012;22:401-15.
19. Detsky AS, Naglie IG. A clinicianâ€™s guide to cost-effectiveness analysis.Ann Intern Med 1990;113:147-54.
20. Lee KK, Bahri S, Talib A, Zainuddin J, Aljunid SM, Sulong S.Pharmacoeconomic Guideline for Malaysia. Malaysia: Ministry of Health Malaysia; 2012.
21. Moradi M, Mousavi S. Drug use evaluation of diabetes mellitus in nonhospitalized patients. Int J Pharm PharmSci 2016;8:337-41.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.